Needle-free subcutaneous sumatriptan for triptan users requiring a change in migraine therapy: Efficacy and impact on patient-rated functionality, satisfaction, and confidence

Current Medical Research and Opinion

Volumn 27, Issue 11, 2011, Pages 2185-2191

  Rothrock, John F ^a   Cady, Roger K ^b   Aurora, Sheena K ^c   Brandes, Jan Lewis ^d   Myers, Judith A ^e   Fox, Anthony W ^e   Farr, Stephen J ^e  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^b HEADACHE CARE CENTER   (United States)

^c Swedish Clinic   (United States)

^d Nashville Neuroscience Group   (United States)

^e Zogenix Inc   (United States)

Author keywords

5HT1B 1D agonist; Headache; Injection; Migraine; Satisfaction; Sumatriptan; Triptan

Indexed keywords

SUMATRIPTAN SUCCINATE;

ADULT; AGED; ANALGESIA; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; FEMALE; FUNCTIONAL STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; PATIENT ATTITUDE; PATIENT CONFIDENCE; PATIENT PERCEPTION OF MIGRAINE QUESTIONNAIRE; PATIENT RATED FUNCTIONALITY; PATIENT SATISFACTION; QUESTIONNAIRE; SCORING SYSTEM; SELF REPORT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; DRUG ADMINISTRATION ROUTES; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; PATIENT SATISFACTION; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SUMATRIPTAN; TREATMENT OUTCOME; TRYPTAMINES; YOUNG ADULT;

EID: 80054688109     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.619177     Document Type: Article

References (28)

1. Dahlof CG. Non-oral formulations of triptans and their use in acute migraine. Curr Pain Headache Rep 2005;9:206-12 (Pubitemid 40873175)
2. Taylor FR. Migraine headache: options for acute treatment. Curr Neurol Neurosci Rep 2005;5:86-92
3. Silberstein SD. Meeting acute migraine treatment needs through novel treatment formulations. Neurotherapeutics 2010;7:153-8
4. Rapoport AM, Tepper SJ, Bigal ME, et al. The triptan formulations: how to match patients and products. CNS Drugs 2003;17:431-47 (Pubitemid 36560705)
5. Kaniecki RG. Mixing sumatriptan: a prospective study of stratified care using multiple formulations. Headache 2001;41:862-6 (Pubitemid 33043149)
6. Gruffydd-Jones K, Hood CA, Price DB. A within-patient comparison of subcutaneous and oral sumatriptan in the acute treatment of migraine in general practice. Cephalalgia 1998;17:31-6 (Pubitemid 27101418)
7. Bigal ME, Bordini CA, Antoniazzi AL, et al. The triptan formulations: a critical evaluation. Arq Neuropsiquiatr 2003;61:313-20 (Pubitemid 36648734)
8. Cady RK, Wendt JK, Kirchner JF, et al. Treatment of acute migraine with subcutaneous sumatriptan. JAMA 1991;265:2831-5
9. Fox AW. Onset of effect of 5-HT1B/1D agonists: a model with pharmacokinetic validation. Headache 2004;44:142-7 (Pubitemid 38233756)
10. Valade D. Early treatment of acute migraine: new evidence of benefits. Cephalalgia 2009;29(Suppl 3):15-21
11. Aurora SK, Barrodale PM, McDonald SA, et al. Revisiting the efficacy of sumatriptan therapy during the aura phase of migraine. Headache 2009;49:1001-4
12. Linde M, Mellberg A, Dahlöf C. Subcutaneous sumatriptan provides symptomatic relief at any pain intensity or time during the migraine attack. Cephalalgia 2006;26:113-21
13. Rapoport AM, Freitag F, Pearlman SH. Innovative delivery systems for migraine: the clinical utility of a transdermal patch for the acute treatment of migraine. CNS Drugs 2010;24:929-40
14. Brandes JL, Cady RK, Freitag FG, et al. Needle-free subcutaneous sumatriptan (Sumavel DosePro): bioequivalence and ease of use. Headache 2009;49:1435-44
15. Sumavel DosePro (sumatriptan injection) for subcutaneous use. Prescribing information
16. Freitag FG. Sumatriptan needle-free subcutaneous (Sumavel DosePro) approved for the acute treatment of migraine, with or without aura, and cluster headaches. Expert Rev Neurother 2011;11:481-90
17. Cady RK, Aurora SK, Brandes JL et al. Satisfaction with and confidence in needle-free subcutaneous sumatriptan in patients currently treated with triptans. Headache 2011;51:1201-11
18. Pascual J, Lainez MJ, Baos V, et al. Predictive model for the Migraine-ACT questionnaire in primary care. Curr Med Res Opin 2007;23:3033-9
19. Garcia ML, Baos V, Lainez M, et al. Responsiveness of Migraine-ACT and MIDAS questionnaires for assessing migraine therapy. Headache 2008; 48:1349-55
20. Kilminster SG, Dowson AJ, Tepper SJ, et al. Reliability, validity, and clinical utility of the Migraine-ACT questionnaire. Headache 2006;46:553-62
21. Headache Classification Committee of the International Headache Society. The international classification of headache disorders, 2nd edn. Cephalalgia 2004(Suppl 1):9-160
22. Revicki DA, Kimel M, Beusterien K, et al. Validation of the revised Patient Perception of Migraine Questionnaire: measuring satisfaction with acute migraine treatment. Headache 2006;46:240-52
23. Kimel M, Hsieh R, McCormack J, et al. Validation of the revised Patient Perception of Migraine Questionnaire (PPMQ-R): measuring satisfaction with acute migraine treatment in clinical trials. Cephalalgia 2008;28:510-23 (Pubitemid 351502541)
24. Cady RC, Ryan R, Jhingran P, et al. Sumatriptan injection reduces productivity loss during a migraine attack: results of a double-blind, placebo-controlled trial. Arch Intern Med 1998;158:1013-18 (Pubitemid 28213579)
25. Davies GM, Santanello N, Lipton R. Determinants of patient satisfaction with migraine therapy. Cephalalgia 2000;20:554-60 (Pubitemid 32269473)
26. Lipton RB, Stewart WF. Acute migraine therapy: do doctors know what migraine patients want from therapy? Headache 1999;39(Suppl 2): S20-S26 (Pubitemid 30002025)
27. Bouchard J, Cortelli P, Dahlöf C, et al. A multinational investigation of the impact of subcutaneous sumatriptan. IV: patient satisfaction. Pharmacoeconomics 1997;11(Suppl 1):43-50 (Pubitemid 27286107)
28. Solomon GD, Santanello N. Impact of migraine and migraine therapy on productivity and quality of life. Neurology 2000;55(9 Suppl 2):S29-S35